Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has named Shawn O’Brien as CEO, effective June 30, succeeding Larry Andrews, who announced in March that he was stepping down.
Mr. O’Brien has spent the past 30 years in the pharmaceutical and biotechnology sectors, where he gained extensive global executive leadership experience. He is one of three founders of AltheRx Pharmaceuticals, where he served as president and CEO.
Previous roles as president and CEO include Profectus BioSciences and Solstice Neurosciences. He earlier held multiple senior-level positions over 17 years with AstraZeneca Pharmaceuticals in Canada and the U.S., and began his career with Upjohn Co. of Canada.
“Shawn has a very unique background, including a proven track record with commercial-stage companies in Canada and the U.S. and a blend of business development, sales & marketing, regulatory and R&D experience,” Cipher chairman, Gerry McDole, said in a statement. “His background aligns very well with Cipher’s core capabilities and growth aspirations.”
Mr. O’Brien said it is rare to find a company that is as well positioned as Cipher, “with increasing revenue, a strong balance sheet, and experienced core team. I am very excited by the opportunity to build on these strengths and help execute the growth plan.”